

2/22




FIG. 2.

000100 22522500




FIG. 3.

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

4/22

FIG. 4.

50

54

55

56

57

50a 60a 70a 51 52 53

△ TPMS Patient

Medical History | Chart | Therapy Evaluation

General

Patient Id: TPMS Number:

Birth Date: [Copy] Gender:

☐ Entry ☐ Print ☐ Save

Weight (kg) + H Date Value

Can Take + H Solid Dosage + H

CD4 and Viral Load

Specimen Date Value Specimen Date Prev Value

(cells/cubic mm) + H

Viral Load + H

(copies/ml)

AIDS Diagnosis AIDS Defining Event + H

Date

Current ARV Therapy + X H

Non-Arv Drugs + X H

Therapy Drug Start Date

Values(s)

Specimen Date

HIV Genotype + H

Phenotype + H

ARV Allergy + H

Intolerance + H

Hemoglobin

Specimen Date Value (g/dL) Date Value

Neuropathy

Neutrophils

Specimen Date cells/cubic mm

Pancreatitis

Specimen Date Value

Hepatic Function

Specimen Date AST/SGOT (U/L)

ALT/SGPT (U/L)

Renal Function

Specimen Date + H

Specimen Date Serum Creatinine

Dialysis Est Creatinine

5/22

60




FIG. 5.

TO FIG. 6B.

FROM FIG. 6A.

FIG. 6B.

Icon	Meaning
○	Indicates that there were no critical alerts for the therapy, however, general warnings and advisories should be read in the Therapy Details box.
ⓘ	Indicates that there were no critical alerts for the therapy, however, general warnings and advisories should be read in the Therapy Details box. The book indicates that therapy has been studied and a reference is available to review.
△	Indicates a yellow alert. There is important information about this therapy that must be reviewed.
⚠	Indicates a yellow alert. There is important information about this therapy that must be reviewed. The book indicates that therapy has been studied and a reference is available to review.
!	Indicates a red alert, which means critical and possible life-threatening situation may exist or may be created with this therapy. Information in the Therapy Details section must be read for this therapy to be considered.
! ⓘ	Indicates a red alert, which means critical and possible life-threatening situation may exist or may be created with this therapy. Information in the Therapy Details section must be read for this therapy to be considered. The book indicates that therapy has been studied and a reference is available to review.
X	Indicates the therapy is not recommended.

9/22

000150 2252250

73a

73b

78

TPMS Patient

Medical History Chart Therapy Evaluation

Therapy Being Evaluated AZT, dd, SQV, RTV

Show Therapies

STOP! - DRUG INTERACTION RED ALERT - STOP!!!

Read the following Red Drug Contra-Indication Alerts for this therapy.

Drug Interaction Alert: Patient is currently taking cisapride, co-administration of Norvir (Ritonavir/RTV) with certain non-sedating antihistamines, sedative hypnotics, or antiarrhythmics may result in potentially serious and/or life-threatening adverse events due to possible effects of Norvir (Ritonavir/RTV) on the hepatic metabolism of certain drugs. Norvir (Ritonavir/RTV) can produce large increases in plasma concentrations of certain highly metabolized drugs. Norvir (Ritonavir/RTV) should not be coadministered with alprazolam, amiodarone, astemizole, bepridil, bupropion, cisapride, clarazepate, clozapine, diazepam, encainide, estazolam, flecainide, flurazepam, mependine, midazolam, piroxicam, propafenone, propoxyphene, quinidine, rifabutin, terfenadine, triazolam or zolpidem. Patient is taking cisapride and in order to use this therapy, that drug should be replaced with a non-contraindicated substitute. CmtDIL, Commentary25

Dosages

- Retrovir 300mg qd 2h (2 pills/day, \$9.56/day)
- Videx 125mg qd 2h (4 pills/day, \$4.22/day)
- Inivase 400mg qd 2h; taken within 2 hours after a full meal (4 pills/day, \$8.47/day)
- Norvir 400mg qd 2h (8 pills/day, \$14.84/day)

(C indicates adjusted dosage)

Dosage Adjustments: The following dosage adjustments messages apply to this therapy.

- Dosage Notice: This therapy contains both saquinavir and ritonavir. When ritonavir and saquinavir are used together the dosage of each drug is reduced by 1/3. The dosage for these drugs has been set accordingly. DosComb, Commentary28

Inivase (saquinavir/SQV): The following Warnings and Advisories apply to Inivase (saquinavir/SQV):

- Drug Interaction Information: Compounds that are substrates of CYP3A4 (e.g., calcium channel blockers, clindamycin, dapsone, quinidine, triazolam) may have elevated plasma concentrations when coadministered with Inivase (saquinavir/SQV); therefore, patient should be monitored for toxicities associated with such drugs when taking Inivase (saquinavir/SQV). CmtGenF, Commentary21

FIG. 8.

[illegible]

FIG. 9.

50

FIG. 10A.

13


70

FIG. 10B.

73

13/22

FIG. 10C.



70

FIG. 10D.

50

FIG. 11A.

FIG. 11B.

FIG. 11C.

TPMS Patient

Medical History | Chart

Therapy Evaluation

Evaluate Current Therapy

None

Show 1-Drug Therapies

Show 2-Drug Therapies

Show 3-Drug Therapies

Show 4-Drug Therapies

Show Rejected Therapies

Show EAP Therapies

Therapy Options (10 of 613)

Clear All Drugs

Therapy	Eff.	Adj.	Safety Considerations	Freq.	Pills	Cost
⊖ AZT, ddI, 3TC, SQV-SGC	1	1		q8h	26	\$43.46
○ ddI, 3TC, NFV	1	1		q8h	13	\$34.78
⊖ AZT, 3TC, IDV	1	1		q8h	10	\$32.24
⊖ AZT, 3TC, NFV	1	1		q8h	13	\$35.81
⊖ ddI, 3TC, IDV	1	1		q8h	10	\$31.20
⊖ AZT, ddI, RTV, DLV	2	2	DLV+RTV	q8h	30	\$45.99
○ ddI, ddI, IDV, NVP	2	2		q8h	17	\$42.55
○ ddI, 3TC, RTV	2	2		q12h	16	\$38.46
○ AZT, ddI, RTV, NVP	2	2		q12h	20	\$47.10

76

See More

See All

Top 10

Full Screen Evaluation

Therapy Being Evaluated

None

General Messages

- WARNING: Before initiating any antiRetroviral treatment regimen, the complete product information for each therapeutic component should be consulted. CmtGanY, Commentary65
- Viral Load Testing Required: Viral load testing should be repeated 21-35 days after initiation of, or a change of, antiRetroviral therapy to evaluate therapeutic efficacy and patient compliance. CmtGanY, Commentary65

Therapy Initiation/Change Messages


- Therapy Initiation: Current treatment guidelines recommend initiation of antiRetroviral therapy for HIV-infected patients with HIV RNA (viral load) concentrations greater than 20,000 copies/ml (10,000 Eq/ml bDNA) or CD4 counts less than 500 cells/μL (Ann.Int.Med., 1998). PreQualM, Commentary61
- Combination Therapy Recommended: Experts agree that the goal of antiRetroviral therapy should be to reduce the viral load to as low a level as possible for as long as possible. Initiation of therapy with a combination containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a potent protease inhibitor have been shown to provide enhanced clinical benefit versus 2 drug combinations with regard to reduction in viral load and improved clinical outcomes. PreQualM, Commentary66

18/22

60a 70a

FIG. 11D.

△ TPMS Patient	
Medical History	Chart Therapy Evaluation
Therapy Being Evaluated	
AZT, ddl, RTV, DLV	
<input type="button" value="Show Therapies"/>	
<input type="button" value="Use as Current Therapy"/>	
<input type="button" value="X"/>	

 Recommended Dosages

























- Retrovir 300mg q 12h (2 pills/day, \$9.56/day)
- Videx 200mg q 12h (4 pills/day, \$6.78/day)
- Norvir 600 mg q 12h (12 pills/day, \$22.26/day)
- Rescriptor 400mg q 8h (12 pills/day, \$7.39/day)

Warnings and Side Effects

- AZT: Interrupt Retroviruse if anemia and/or neutropenia develops. More Info 036 DosGenA, Commentary36
- ddl: When treatment with other drugs known to cause pancreatic toxicity is required (for example, IV pentamidine), suspension of Videx should be considered. CmtGenA, Commentary13
- ddl: If patients develop symptoms of neuropathy, Videx therapy should be interrupted. DosGenB, Commentary40
- ddl: Clinical signs suggestive of pancreatitis should prompt dose suspension of Videx and careful evaluation of the possibility of pancreatitis. Only after pancreatitis has been ruled out should dosing be resumed. DosGenB, Commentary39
- DLV: Skin rash attributable to Rescriptor may occur during first 21 days. More Info 054 CmtGenS, Commentary54

Drug Interaction Information

- ddl: Videx should not be administered with a prescription antibiotic containing any form of tetracycline. CmtGenA, Commentary15
- ddl: Plasma concentrations of some quinolone antibiotics are decreased when administered with antacids containing magnesium or aluminum. Therefore, doses of quinolone antibiotics should not be administered within 2 hours of taking Videx. CmtGenA, Commentary16
- RTV: Monitor for decreased AUC of Norvir and associated adverse events when concomitant with use of drugs that increase CYP3A activity (including tobacco). More Info 026 CmtGenH, Commentary26

TPMS																								
------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------

TPMS Patient		Therapy Evaluation		
Medical History Chart				
<input type="checkbox"/> Show 1-Drug Therapies <input checked="" type="checkbox"/> Show 3-Drug Therapies <input type="checkbox"/> Show Rejected Therapies <input type="checkbox"/> Show 2-Drug Therapies <input checked="" type="checkbox"/> Show 4-Drug Therapies <input type="checkbox"/> Show Exp Therapies		None		
Evaluate Current Therapy?				
Therapy Options (10 of 613)				
Therapy	Show Abstract for Retrovir	Freq.	Pills	Cost
<input checked="" type="radio"/> AZT, ddI, 3TC, SQV-S	Show Abstract for Video	q8h	26	\$43.46
<input type="radio"/> d4T, 3TC, NFV	Show Abstract for Epiw	q8h	13	\$34.78
<input checked="" type="radio"/> AZT, 3TC, IDV	Show Abstract for Fortvase	q8h	10	\$32.24
<input checked="" type="radio"/> AZT, 3TC, NFV	Show Therapy Study	q8h	13	\$35.81
<input checked="" type="radio"/> d4T, 3TC, IDV		q8h	10	\$31.20
<input type="radio"/> AZT, ddI, RTV, DLV	Print Details for AZT, ddI, 3TC, SQV-SGC	q8h	30	\$45.99
<input type="radio"/> d4T, IDV, NVP	Print Top 10 Therapy Option Details	q8h	17	\$42.55
<input type="radio"/> d4T, 3TC, RTV	Print All Therapy Option Summaries	q12h	16	\$38.46
<input type="radio"/> AZT, ddI, RTV, NVP	Print Top 10 Therapy Option Summaries	q12h	20	\$47.10
See More	Hide Column "Eff."			
See All	Hide Column "Adj."			
See All	Hide Column "Safety Considerations"			
See All	Show Column "Med"			
See All	Show Column "Drug"			
See All	Hide Column "Freq."			
See All	Hide Column "Pills"			
See All	Hide Column "Cost"			
Therapy Being Evaluated				
General Message				
<p>• WARNING--Before initiating any antiRetroviral treatment regimen, the complete product information for each therapeutic component should be consulted. CmtGenY, Commentary35</p> <p>• Viral Load Testing Required: Viral load testing should be repeated 21-35 days after initiation of, or a change of, antiRetroviral therapy to evaluate therapeutic efficacy and patient compliance. CmtGenY, Commentary65</p>				
 W1 A1 A2 A3				
Therapy Initiation/Change Messages				
<p>• Therapy Initiation: Current treatment guidelines recommend initiation of antiRetroviral therapy for HIV-infected patients with HIV RNA (viral load) concentrations greater than 20,000 copies/ml (10,000 Eq/ml bDNA) or CD4 counts less than 500 cells/uL (Ann.Int.Med., 1998). PreQualIM, Commentary61</p> <p>• Combination Therapy Recommended: Experts agree that the goal of antiRetroviral therapy should be to reduce the viral load to as low a level as possible for as long as possible. Initiation of therapy with a combination containing 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a potent protease inhibitor have been shown to provide enhanced clinical benefit versus 2 drug combinations with regard to reduction in viral load and improved clinical outcomes. PreQualIM, Commentary66</p>				




FIG. 12A.

000000 22522560

FIG. 12B.

TPMS Patient		Medical History Chart		Therapy Evaluation																																																		
Evaluate Current Therapy <input checked="" type="checkbox"/> 3TC, d4T, NVP		<input type="checkbox"/> Show 1-Drug Therapies <input type="checkbox"/> Show 2-Drug Therapies		<input checked="" type="checkbox"/> Show 3-Drug Therapies <input type="checkbox"/> Show 4-Drug Therapies <input type="checkbox"/> Show EAP Therapies																																																		
Therapy Options (10 of 98) <table border="1" style="width:100%; border-collapse: collapse; font-size: small;"> <thead> <tr> <th>Therapy</th> <th>Efficacy</th> <th>Adj.</th> <th>Safety Considerations</th> <th>Freq.</th> <th>Pills</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td>△ ddI, d4T, NFV</td> <td>2</td> <td>2</td> <td>Ribavirin+NFV</td> <td>q8h</td> <td>15</td> <td>\$33.88</td> </tr> <tr> <td>○ ddI, d4T, EFV</td> <td>5</td> <td>5</td> <td></td> <td>q12h</td> <td>9</td> <td>\$28.44</td> </tr> <tr> <td>△ ddI, NFV, EVF</td> <td>5</td> <td>5</td> <td>Ribavirin+NFV</td> <td>q8h</td> <td>16</td> <td>\$38.50</td> </tr> <tr> <td>△ d4T, NFV, EVF</td> <td>5</td> <td>5</td> <td>Ribavirin+NFV</td> <td>q8h</td> <td>14</td> <td>\$40.24</td> </tr> <tr> <td>△ ddC, NFV, EVF</td> <td>5</td> <td>7</td> <td>Ribavirin+NFV</td> <td>q8h</td> <td>15</td> <td>\$38.77</td> </tr> <tr> <td>○ ddC, d4T, EFV</td> <td>5</td> <td>7</td> <td></td> <td>q8h</td> <td>8</td> <td>\$28.71</td> </tr> </tbody> </table>		Therapy	Efficacy	Adj.	Safety Considerations	Freq.	Pills	Cost	△ ddI, d4T, NFV	2	2	Ribavirin+NFV	q8h	15	\$33.88	○ ddI, d4T, EFV	5	5		q12h	9	\$28.44	△ ddI, NFV, EVF	5	5	Ribavirin+NFV	q8h	16	\$38.50	△ d4T, NFV, EVF	5	5	Ribavirin+NFV	q8h	14	\$40.24	△ ddC, NFV, EVF	5	7	Ribavirin+NFV	q8h	15	\$38.77	○ ddC, d4T, EFV	5	7		q8h	8	\$28.71	Antiretroviral Drugs Clear All Drugs Nucleoside Analogues (NRTI) ② AZT (Retrovir/zidovudine) ① ddI (Videx/didanosine) ① ddC (Hivid/zalcitabine) ② 3TC (Epivir/lamivudine) ④ Zalcitabine (ddC) ③ ABC (Zegenixabacavir)			
Therapy	Efficacy	Adj.	Safety Considerations	Freq.	Pills	Cost																																																
△ ddI, d4T, NFV	2	2	Ribavirin+NFV	q8h	15	\$33.88																																																
○ ddI, d4T, EFV	5	5		q12h	9	\$28.44																																																
△ ddI, NFV, EVF	5	5	Ribavirin+NFV	q8h	16	\$38.50																																																
△ d4T, NFV, EVF	5	5	Ribavirin+NFV	q8h	14	\$40.24																																																
△ ddC, NFV, EVF	5	7	Ribavirin+NFV	q8h	15	\$38.77																																																
○ ddC, d4T, EFV	5	7		q8h	8	\$28.71																																																
See More See All Top 10 Full Screen Evaluation				Protease Inhibitors (PI) <Use as Current Therapy																																																		
Therapy Being Evaluated 3TC, d4T, NVP		<div style="text-align: center;"> !!! THERAPY REJECTED !!! This therapy was rejected for the following reason(s): Additional information about the therapy is provided but this therapy is NOT advisable </div>																																																				
<ul style="list-style-type: none"> • Viramune (nevirapine/NVP) Resistance Advisory: According to the last genotype data entered, the patient's virus currently has mutation(s) which are associated with resistance to Viramune. FIRMutE, Rejection54 • Resistance Advisory: According to the last genotype data entered, the patient's virus currently has the following mutations: M184V [RT], the genotype test displays evidence of the M184V/M184L mutation which is associated with resistance to 3TC. However, this mutant has increased sensitivity to the antiretroviral activity of AZT and ADV so an AZT/3TC or AZT/ADV combination is still useable. Therefore combinations which contain AZT/3TC and AZT/ADV are shown as therapy options although these therapies have been ranked down +5 in favor of three drug combinations with no resistant mutants. FIRMutB, Rejection51 • Epivir and Viramune Resistance Advisory: The patient's last phenotypic assay demonstrates phenotypic resistance to Epivir and Viramune, therefore, therapies containing Epivir and Viramune are not recommended at this time. FIRMutC, Rejection42 • NVP Δ : Drug Interaction Alert: Patient is currently taking ribavirin and there is insufficient data to assess whether dose adjustments are necessary. These drugs 																																																						
Warnings CAUTION YELLOW ALERT CAUTION		W3																																																				

FIG. 12C.

<div style="display: flex; justify-content: space-between;"> TPMS Patient Medical History Chart Therapy Evaluation </div>																									
<div style="display: flex; justify-content: space-between;"> <div> General Patient Id: Features1 Physician: ipatient </div> <div> Birth date: 1/1/1960 Gender: Male </div> <div> TPMS Number: Print Save </div> <div> <input type="checkbox"/> + <input type="checkbox"/> H <input type="checkbox"/> Entry <input type="checkbox"/> Comment Popu </div> </div>		<div style="display: flex; justify-content: space-between;"> <div> Weight (kg) <input type="checkbox"/> + <input type="checkbox"/> H 60.00 Solid Dosage <input type="checkbox"/> + <input type="checkbox"/> H 12/28/1999 Yes </div> <div> Date 1/28/1999 Value 60.00 </div> </div>																							
CD4 and Viral Load <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Specimen Date</th> <th>Value</th> <th>Specimen Date</th> <th>Prev Value</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999</td> <td>240</td> <td>1/28/1999</td> <td>265</td> </tr> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999</td> <td>21500</td> <td>VL Units:</td> <td>C/mL</td> </tr> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>2600</td> <td>VL Units:</td> <td>C/mL</td> </tr> </tbody> </table>		Specimen Date	Value	Specimen Date	Prev Value	<input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999	240	1/28/1999	265	<input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999	21500	VL Units:	C/mL	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	2600	VL Units:	C/mL	AIDS Diagnosis <input type="checkbox"/> + <input type="checkbox"/> H Date <input type="checkbox"/> + <input type="checkbox"/> H AIDS Defining Event Current ARV Therapy <input type="checkbox"/> V <input type="checkbox"/> D <input type="checkbox"/> + <input type="checkbox"/> X <input type="checkbox"/> H 11/4/1998 3TC, d4T, NVP 54C Non-ARV Drugs <input type="checkbox"/> + <input type="checkbox"/> X <input type="checkbox"/> H Start Date 5/1/1999 5/1/1999 5/1/1999							
Specimen Date	Value	Specimen Date	Prev Value																						
<input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999	240	1/28/1999	265																						
<input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999	21500	VL Units:	C/mL																						
<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	2600	VL Units:	C/mL																						
HIV Genotype <input type="checkbox"/> + <input type="checkbox"/> H 3/15/1999 [L101P], M45[P], L54V[P], V82A[P], M41L[RT], Y181 Ph <input type="checkbox"/> + <input type="checkbox"/> H AI <input type="checkbox"/> + <input type="checkbox"/> H In <input type="checkbox"/> + <input type="checkbox"/> H		<div style="border: 1px solid black; padding: 5px;"> <p>• NVP△: Drug Interaction Alert: Patient is currently taking rifabutin and there is insufficient data to assess whether dose adjustments are necessary. These drugs should only be used in combination if clearly indicated and with careful monitoring. CmtDIP, Commentary33</p> </div>																							
Hemoglobin <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Specimen Date</th> <th>Value(g/dL)</th> <th>Date</th> <th>Value</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>15.00</td> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>No</td> </tr> </tbody> </table>		Specimen Date	Value(g/dL)	Date	Value	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	15.00	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	No	Neuropathy <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Specimen Date</th> <th>Value</th> <th>Date</th> <th>Value</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>1500</td> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>No</td> </tr> </tbody> </table>		Specimen Date	Value	Date	Value	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	1500	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	No						
Specimen Date	Value(g/dL)	Date	Value																						
<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	15.00	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	No																						
Specimen Date	Value	Date	Value																						
<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	1500	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	No																						
Neutrophils <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Specimen Date</th> <th>cells/cubic mm</th> <th>Date</th> <th>Value</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>1500</td> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>No</td> </tr> </tbody> </table>		Specimen Date	cells/cubic mm	Date	Value	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	1500	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	No	Renal Function <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>Specimen Date</th> <th>AST/SGOT (IU/L)</th> <th>ALT/SGPT (IU/L)</th> <th>Specimen Date</th> <th>Dialysis</th> <th>Serum Creatinine</th> <th>Est. Creatinine</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999</td> <td>25</td> <td>25</td> <td>1/28/1999</td> <td>No</td> <td>1.00</td> <td>84.17</td> </tr> </tbody> </table>		Specimen Date	AST/SGOT (IU/L)	ALT/SGPT (IU/L)	Specimen Date	Dialysis	Serum Creatinine	Est. Creatinine	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	25	25	1/28/1999	No	1.00	84.17
Specimen Date	cells/cubic mm	Date	Value																						
<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	1500	<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	No																						
Specimen Date	AST/SGOT (IU/L)	ALT/SGPT (IU/L)	Specimen Date	Dialysis	Serum Creatinine	Est. Creatinine																			
<input type="checkbox"/> + <input type="checkbox"/> H 1/28/1999	25	25	1/28/1999	No	1.00	84.17																			